Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03655002
Title IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

hepatocellular carcinoma

Therapies

Cyclophosphamide + IRX-2 + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.